Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2023-187795

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood (2023) 142 (Supplement 1): 58.

https://doi.org/10.1182/blood-2023-182337

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood (2023) 142 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2023-190400

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Blood (2023) 142 (Supplement 1): 870.

https://doi.org/10.1182/blood-2023-188236

Published: 2023

Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Blood (2022) 140 (Supplement 1): 8966–8968.

https://doi.org/10.1182/blood-2022-157358

Published: 2022

Journal Articles

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Jayastu Senapati, Farhad Ravandi, Courtney D. DiNardo, Ghayas C. Issa, Koji Sasaki, Marina Konopleva, Naveen Pemmaraju, Kelly S. Chien, Maro Ohanian, Elias Jabbour, Abhishek Maiti, Edith Roy, Ricardo Delumpa, Juan Rivera, Christopher Loiselle, Glenda Banks, Hagop Kantarjian, Nicholas Short

Blood (2022) 140 (Supplement 1): 3880–3882.

https://doi.org/10.1182/blood-2022-170773

Published: 2022

Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda

Blood (2022) 140 (Supplement 1): 9876–9878.

https://doi.org/10.1182/blood-2022-167284

Published: 2022

Journal Articles

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Blood (2022) 140 (Supplement 1): 7725–7728.

https://doi.org/10.1182/blood-2022-169896

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla

Blood (2022) 139 (6): 907–921.

https://doi.org/10.1182/blood.2021013156

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 367.

https://doi.org/10.1182/blood-2021-147360

Published: 2021

NARROW

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only